Found 43 clinical trials
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) represents the formalized integration of ARTFL (U54 NS092089; funded through 2019) and LEFFTDS (U01 AG045390; funded through 2019) as a single North American research consortium to study FTLD for 2019 and beyond.
- 236 views
- 28 May, 2022
- 23 locations
Modifiable Variables in Parkinsonism (MVP)
We are trying to identify factors associated with improved quality of life and fewer PD symptoms. We are attempting to identify practices, beliefs, and therapies used by individuals who report excellent quality of life, few PD symptoms, and reduced rates of progression. After agreeing to participate, we will ask participants …
- 282 views
- 05 Apr, 2022
- 1 location
UPenn Observational Research Repository on Neurodegenerative Disease (UNICORN)
The aim of this study is to create a repository of both cross-sectional and longitudinal data, including cognitive, linguistic, imaging and biofluid biological specimens, for neurodegenerative disease research and treatment.
- 1 views
- 25 Mar, 2022
- 1 location
4 Repeat Tauopathy Neuroimaging Initiative (4RTNI)
The purpose of this study is to evaluate several different tests, including brain imaging, eye movement testing, body fluid samples, measurements of memory and other thinking abilities, and measures of functional independence in the hope that this information can be used to guide diagnosis and treatment of PSP and CBD …
- 157 views
- 26 Jan, 2022
- 2 locations
Oxford Study of Quantification in Parkinsonism (OxQUIP)
The OxQUIP (Oxford QUantification In Parkinsonism) study is recruiting patients with Parkinson's Disease and Progressive Supranuclear Palsy. Currently available treatments for these diseases are
- 1 views
- 26 Jan, 2022
- 1 location
Biomarkers in Parkinsonian Syndromes (BIOPARK)
Parkinson disease (PD), multiple system atrophy (MSA) and progressive supranuclear palsy (PSP) are neurodegenerative disorders. PD and MSA are alpha-synucleinopathies, which are characterized by
- 248 views
- 19 Apr, 2022
- 2 locations
Facilitating Diagnostics and Prognostics of Parkinsonian Syndromes Using Neuroimaging
The goals of this study are: 1) to identify biomarkers using neuroimaging that are associated with progression rate using statistical methods, and 2) to identify biomarkers that are associated with the differential diagnosis of Parkinson's disease and atypical parkinsonism.
- 155 views
- 25 Mar, 2022
- 1 location
Tau Protein and SV2a Imaging in Patients With Tau Protein-related Diseases
Tau protein has been identified as one of the key pathological features of Tau proteinopathies, such as Alzheimer's disease (AD), progressive supranuclear palsy (PSP), frontotemporal dementia
- 0 views
- 14 Mar, 2022
- 1 location
Misfolded Proteins in the Skin of People With Parkinson's Disease and Other Parkinsonism
someone has a synucleinopathy such as Parkinson's disease (PD), multiple system atrophy (MSA), or dementia with Lewy bodies(DLB), as opposed to a tauopathy such as progressive supranuclear palsy (PSP) or
- 24 views
- 23 Apr, 2022
- 2 locations
Investigating Complex Neurodegenerative Disorders Related to Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
Background Neurodegenerative disorders can lead to problems in movement or memory. Some can cause abnormal proteins to build up in brain cells. Researchers want to understand whether these diseases have related causes or risk factors. Objective To test people with movement or thinking and memory problems to see if they …
- 61 views
- 27 Jun, 2022
- 1 location